UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Quantitative lymph node burden as a ‘very-high-risk’ factor identifying head and neck cancer patients benefiting from postoperative chemoradiation

Annals of oncology, 2019-01, Vol.30 (1), p.76-84

2019

Volltextzugriff (PDF)

Quantitative lymph node burden as a ‘very-high-risk’ factor identifying head and neck cancer patients benefiting from postoperative chemoradiation

Annals of oncology, 2019-10, Vol.30 (10), p.1669-1669

2019

Volltextzugriff (PDF)

Interim Analysis of a Phase I Study of Veliparib With Gemcitabine and IMRT in Patients With Borderline and Locally Advanced Unresectable Pancreatic Cancer

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.E181-E181

2015

Volltextzugriff (PDF)

A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies

British journal of cancer, 2013-03, Vol.108 (4), p.762-765

2013

Volltextzugriff (PDF)

Margin Clearance and Lymphadenectomy in Pancreatic Adenocarcinoma: Clinical Outcomes and Implications for Adjuvant Radiation Therapy

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.E158-E158

2015

Volltextzugriff (PDF)

Restoration of caveolin-1 expression suppresses growth and metastasis of head and neck squamous cell carcinoma

British journal of cancer, 2008-11, Vol.99 (10), p.1684-1694

2008

Volltextzugriff (PDF)

Distant Metastases Are The Major Concern In Malignant Salivary Gland Tumors

International journal of radiation oncology, biology, physics, 2011, Vol.81 (2), p.S525-S525

2011

Volltextzugriff (PDF)

Optimal Timing of Radiation Therapy for Non-parameningeal Pediatric Rhabdomyosarcoma

International journal of radiation oncology, biology, physics, 2011, Vol.81 (2), p.S661-S661

2011

Volltextzugriff (PDF)

A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer

EBioMedicine, 2019-02, Vol.40, p.375-381

2019

Volltextzugriff (PDF)

DNA Repair Deficiency, Genomic Instability and Immune Profiling in a Phase 1 Study of Locally Advanced Pancreatic Cancer Patients Treated with Veliparib, Gemcitabine and Radiation Therapy

International journal of radiation oncology, biology, physics, 2018-11, Vol.102 (3), p.S135-S136

2018

Volltextzugriff (PDF)

Incidence, Risk, and Sequelae of Posterior Fossa Syndrome in Pediatric Medulloblastoma

International journal of radiation oncology, biology, physics, 2008, Vol.72 (1), p.S81-S81

2008

Volltextzugriff (PDF)

Abstract OT3-04-02: Neoadjuvant Her2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT3-04-02-OT3-04-02

2019

Volltextzugriff (PDF)

287TiP - Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial

Annals of oncology, 2019-10, Vol.30, p.v96-v97

2019

Volltextzugriff (PDF)

287TiPNeoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial

Annals of oncology, 2019-10, Vol.30, p.v96-v97

2019

Volltextzugriff (PDF)

Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control

Statistics in medicine, 2005-07, Vol.24 (14), p.2183-2196

2005

Volltextzugriff (PDF)

Survival Impact of Treatment Interval Delays in Head and Neck Cancer

International journal of radiation oncology, biology, physics, 2018-04, Vol.100 (5), p.1322-1323

2018

Volltextzugriff (PDF)

GFR Decline as an Alternative End Point to Kidney Failure in Clinical Trials: A Meta-analysis of Treatment Effects From 37 Randomized Trials

American journal of kidney diseases, 2014-12, Vol.64 (6), p.848-859

2014

Volltextzugriff (PDF)

GFR Decline and Subsequent Risk of Established Kidney Outcomes: A Meta-analysis of 37 Randomized Controlled Trials

American journal of kidney diseases, 2014-12, Vol.64 (6), p.860-866

2014

Volltextzugriff (PDF)

Cognitive Decline and Its Risk Factors in Prevalent Hemodialysis Patients

American journal of kidney diseases, 2017-06, Vol.69 (6), p.780-787

2017

Volltextzugriff (PDF)

Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane‐refractory/resistant nonsmall cell lung carcinoma

Cancer, 2005-08, Vol.104 (3), p.561-569

2005

Volltextzugriff (PDF)

Anatomic Brain Disease in Hemodialysis Patients: A Cross-sectional Study

American journal of kidney diseases, 2013-02, Vol.61 (2), p.271-278

2013

Volltextzugriff (PDF)

Non-GFR Determinants of Low-Molecular-Weight Serum Protein Filtration Markers in CKD

American journal of kidney diseases, 2016-12, Vol.68 (6), p.892-900

2016

Volltextzugriff (PDF)

GFR Estimation Using β-Trace Protein and β2 -Microglobulin in CKD

American journal of kidney diseases, 2016-01, Vol.67 (1), p.40-48

2016

Volltextzugriff (PDF)

Urine Potassium Excretion, Kidney Failure, and Mortality in CKD

American journal of kidney diseases, 2017-03, Vol.69 (3), p.341-349

2017

Volltextzugriff (PDF)

1 – 25 von 238

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(230)
Mit Volltextzugriff
(220)

Publikationsform

Sprache

Englisch
(233)
Französisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Quantitative lymph node burden as a ‘very-high-risk’ factor identifying head and neck cancer patients benefiting from postoperative chemoradiation

Quantitative lymph node burden as a ‘very-high-risk’ factor identifying head and neck cancer patients benefiting from postoperative chemoradiation

Interim Analysis of a Phase I Study of Veliparib With Gemcitabine and IMRT in Patients With Borderline and Locally Advanced Unresectable Pancreatic Cancer

A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies

Margin Clearance and Lymphadenectomy in Pancreatic Adenocarcinoma: Clinical Outcomes and Implications for Adjuvant Radiation Therapy

Restoration of caveolin-1 expression suppresses growth and metastasis of head and neck squamous cell carcinoma

Distant Metastases Are The Major Concern In Malignant Salivary Gland Tumors

Optimal Timing of Radiation Therapy for Non-parameningeal Pediatric Rhabdomyosarcoma

A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer

DNA Repair Deficiency, Genomic Instability and Immune Profiling in a Phase 1 Study of Locally Advanced Pancreatic Cancer Patients Treated with Veliparib, Gemcitabine and Radiation Therapy

Incidence, Risk, and Sequelae of Posterior Fossa Syndrome in Pediatric Medulloblastoma

Abstract OT3-04-02: Neoadjuvant Her2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial

287TiP - Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial

287TiPNeoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial

Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial

Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control

Survival Impact of Treatment Interval Delays in Head and Neck Cancer

GFR Decline as an Alternative End Point to Kidney Failure in Clinical Trials: A Meta-analysis of Treatment Effects From 37 Randomized Trials

GFR Decline and Subsequent Risk of Established Kidney Outcomes: A Meta-analysis of 37 Randomized Controlled Trials

Cognitive Decline and Its Risk Factors in Prevalent Hemodialysis Patients

Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane‐refractory/resistant nonsmall cell lung carcinoma

Anatomic Brain Disease in Hemodialysis Patients: A Cross-sectional Study

Non-GFR Determinants of Low-Molecular-Weight Serum Protein Filtration Markers in CKD

GFR Estimation Using β-Trace Protein and β2 -Microglobulin in CKD

Urine Potassium Excretion, Kidney Failure, and Mortality in CKD

Suchergebnisse filtern